Search research articles
Contact Us
Filters
Showing results (111-120 of 183) with videos related to
Page
of 19
Sort By:
American Journal of Hematology
|
February 16, 2022
Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume
Ho-Young Yhim, Yael Eshet, Ur Metser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2003
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
Lauren E Abrey, Craig H Moskowitz, Warren P Mason, et al.
Advances in Radiation Oncology
|
April 28, 2025
Outcomes of Primary Mediastinal B-cell Lymphoma Patients with Partial Metabolic Response: A Multicenter Retrospective Analysis
Nattinee Wattakiyanon, Mahmood Aminilari, Xiang Y Ye, et al.
Practical Radiation Oncology
|
March 1, 2026
Management and Outcomes for Hodgkin's Lymphoma Patients with Partial Metabolic Response after First-Line Systemic Therapy
Donna Liao, Mahmood Aminilari, Xiang Y Ye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
Laurie H Sehn, David MacDonald, Sheldon Rubin, et al.
Leukemia & Lymphoma
|
June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
Rena Buckstein, Graeme Fraser, Matthew Cheung, et al.
Eneuro
|
December 12, 2019
Toric Spines at a Site of Learning
Daniel Sanculi, Katherine E Pannoni, Eric A Bushong, et al.
BMC Cancer
|
August 14, 2014
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
Sara Khor, Jaclyn Beca, Murray Krahn, et al.
Current Oncology (Toronto, Ont.)
|
July 28, 2023
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey
Esmail M Al-Ezzi, Amer Zahralliyali, Aaron R Hansen, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 183) with videos related to
Sort By:
Page
of 19
American Journal of Hematology
|
February 16, 2022
Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume
Ho-Young Yhim, Yael Eshet, Ur Metser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2003
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
Lauren E Abrey, Craig H Moskowitz, Warren P Mason, et al.
Advances in Radiation Oncology
|
April 28, 2025
Outcomes of Primary Mediastinal B-cell Lymphoma Patients with Partial Metabolic Response: A Multicenter Retrospective Analysis
Nattinee Wattakiyanon, Mahmood Aminilari, Xiang Y Ye, et al.
Practical Radiation Oncology
|
March 1, 2026
Management and Outcomes for Hodgkin's Lymphoma Patients with Partial Metabolic Response after First-Line Systemic Therapy
Donna Liao, Mahmood Aminilari, Xiang Y Ye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
Laurie H Sehn, David MacDonald, Sheldon Rubin, et al.
Leukemia & Lymphoma
|
June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
Rena Buckstein, Graeme Fraser, Matthew Cheung, et al.
Eneuro
|
December 12, 2019
Toric Spines at a Site of Learning
Daniel Sanculi, Katherine E Pannoni, Eric A Bushong, et al.
BMC Cancer
|
August 14, 2014
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
Sara Khor, Jaclyn Beca, Murray Krahn, et al.
Current Oncology (Toronto, Ont.)
|
July 28, 2023
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey
Esmail M Al-Ezzi, Amer Zahralliyali, Aaron R Hansen, et al.
Page
of 19